Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Now entering Florida sign with a marijuana leaf on it

Is It Too Late to Buy Trulieve Cannabis Stock?

It depends on the cannabis operator's ability to continue its remarkable growth.

Young woman with drawing of dollar-shaped rocket

Got $5,000? 3 Stocks to Buy That Could Double by 2022

Here's how they could do it.

Holding syringe and vaccine bottle

This Late-to-the-Party Coronavirus Vaccine Maker Could Be the Biggest Winner Over the Long Run

Addressing the limitations of the current leading COVID-19 vaccines could be the key to long-term success.

2 jigsaw puzzle pieces with sun shining

Why AMAG Pharmaceuticals Stock Is Skyrocketing Today

The company is being gobbled up by another drugmaker.

Tablet showing ascending charts

3 Stocks That Look Absurdly Overvalued but Really Aren't

Focusing too much on common valuation metrics can be shortsighted with these high-flying stocks.

Doctor holding COVID-19 vaccine with thumb up

The Biggest Coronavirus Vaccine Winner So Far

It isn't even close.

Cannabis leaf made of $100 bill

Here's 1 Area Where Aurora Cannabis Absolutely Trounces Canopy Growth

It's really no contest.

2 scientists in lab

Better Buy: GlaxoSmithKline vs. Pfizer

One of these big pharma stocks appears to have an advantage.

Sticky note with coronavirus over a dollar sign

Is Moderna Stock a Buy?

The risks are great, but so are the potential rewards.

Hand with DNA helix image

Better Buy: Invitae vs. Illumina

Which stock wins in this genetics version of David versus Goliath?

Pushing frown face icon

Why Axsome Therapeutics Stock Is Sinking Today

An analyst doesn't think very highly of Axsome's prospects.

COVID-19 coronavirus wood blocks

Why Sorrento Therapeutics Stock Is Surging Today

Investors like the biotech's promising preclinical data for two experimental COVID-19 antibody therapies.

IPO and stock chart

Which Hot IPO Stock Is More Likely to Make You Rich: Amwell or GoodRx?

It's not an easy decision.

Hourglass, money, mask

Here's When Bill Gates Thinks the Coronavirus Pandemic Will End

Also, here are some stocks that should be good picks before it ends.

Female scientist holding 2 test tubes

Better Buy: Gilead Sciences vs. Amgen

These big biotechs are both moving into new areas. Which is most likely to move the needle for investors?

Person in lab with vial

Why Eiger BioPharmaceuticals Stock Sank Today

The company reported disappointing news from a clinical study targeting COVID-19 outpatients.

Doctor with mask and hand up

Why Inovio Stock Is Crashing Today

The planned phase 2/3 study of COVID-19 vaccine candidate INO-4800 just hit a major speed bump.

Joe Biden (

Will Marijuana Stocks Soar If Biden Wins and Sink If He Loses?

The answer isn't as clearcut as you might think.

Jigsaw puzzle pieces forming small globe

Here's the Bigger Story About Moderna That You Might Be Missing

The biotech's COVID-19 vaccine could be merely the tip of the iceberg.

Man looking at graphics of virus spread

A Second Wave of Coronavirus Could Be Coming: 3 Stocks to Buy Before It Hits

These stocks are perfectly positioned if the COVID-19 pandemic worsens in the U.S.